The Polyamine Metabolism Genes Ornithine Decarboxylase and Antizyme 2 Predict Aggressive Behavior in Neuroblastomas with and Without MYCN Amplification

Overview

Journal Int J Cancer

Specialty Oncology

Date 2009 Dec 5

PMID 19960435

Citations 31

Authors

Dirk Geerts

Jan Koster

David Albert

Dana-Lynn T Koomoa

David J Feith

Anthony E Pegg

Richard Volckmann

Huib Caron

Rogier Versteeg

Andre S Bachmann

Affiliations

Soon will be listed here.

Abstract

High polyamine (PA) levels and ornithine decarboxylase (ODC) overexpression are well-known phenomena in many aggressive cancer types. We analyzed the expression of ODC and ODC-activity regulating genes antizymes 1-3 (OAZ1-3) and antizyme inhibitors 1-2 (AZ-IN1-2) in human neuroblastoma (NB) tumors and correlated these with genetic and clinical features of NB. Since ODC is a known target gene of MYCN, the correlation between ODC and MYCN was of special interest. Data were obtained from Affymetrix micro-array analysis of 88 NB tumor samples. In addition, mRNA expression levels of ODC, OAZ2 and MYCN in a MYCN-inducible NB cell line were determined by quantitative real-time reverse-transcriptase polymerase chain reaction (RT-PCR). ODC mRNA expression in NB tumors was significantly predictive of decreased overall survival probability and correlated with several unfavorable clinical NB characteristics (all p < 0.005). Interestingly, high ODC mRNA expression also showed significant correlation with poor survival prognosis in Kaplan-Meier analyses stratified for patients without MYCN amplification, suggesting an additional role for ODC independent of MYCN. Conversely, high OAZ2 mRNA expression correlated with increased survival and with several favorable clinical NB characteristics (all p < 0.003). In addition, we provide first evidence of a role for MYCN-associated transcription factors MAD2 and MAD7 in ODC regulation. In NB cell cultures, ectopic overexpression of MYCN altered ODC but not OAZ2 mRNA levels. In conclusion, these data suggest that elevated ODC and low OAZ2 mRNA expression levels correlate with several unfavorable genetic and clinical features in NB, offering new insights into PA pathways and PA metabolism-targeting therapy in NB.

Citing Articles

Ornithine decarboxylase antizyme 2 (OAZ2) in human colon adenocarcinoma: a potent prognostic factor associated with immunity.

Liu Y, Zhang S, Liao W, Qian J, Lu C, Jin L Sci Rep. 2025; 15(1):7481.

PMID: 40032914 PMC: 11876682. DOI: 10.1038/s41598-025-90066-4.

Polyamine Inhibition with DFMO: Shifting the Paradigm in Neuroblastoma Therapy.

Schramm J, Sholler C, Menachery L, Vazquez L, Saulnier Sholler G J Clin Med. 2025; 14(4).

PMID: 40004600 PMC: 11856405. DOI: 10.3390/jcm14041068.

The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma.

Azfar M, Gao W, Van den Haute C, Xiao L, Karsa M, Pandher R Mol Oncol. 2025; 19(3):913-936.

PMID: 39981745 PMC: 11887671. DOI: 10.1002/1878-0261.13789.

Construction of molecular subtype and prognostic model for gastric cancer based on nucleus-encoded mitochondrial genes.

Wang X, Li S, Shen Y, Cao L, Lu Y, Cao J Sci Rep. 2024; 14(1):28491.

PMID: 39557952 PMC: 11574080. DOI: 10.1038/s41598-024-78729-0.

Bachmann-Bupp syndrome and treatment.

Bachmann A, VanSickle E, Michael J, Vipond M, Bupp C Dev Med Child Neurol. 2023; 66(4):445-455.

PMID: 37469105 PMC: 10796844. DOI: 10.1111/dmcn.15687.

References

Albeck S, Dym O, Unger T, Snapir Z, Bercovich Z, Kahana C . Crystallographic and biochemical studies revealing the structural basis for antizyme inhibitor function. Protein Sci. 2008; 17(5):793-802. PMC: 2327289. DOI: 10.1110/ps.073427208. View

Revet I, Huizenga G, Chan A, Koster J, Volckmann R, van Sluis P . The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma. Exp Cell Res. 2008; 314(4):707-19. DOI: 10.1016/j.yexcr.2007.12.008. View

Lutz W, Stohr M, SCHURMANN J, Wenzel A, Lohr A, Schwab M . Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene. 1996; 13(4):803-12. View

Cohn S, London W, Huang D, Katzenstein H, Salwen H, Reinhart T . MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol. 2000; 18(21):3604-13. DOI: 10.1200/JCO.2000.18.21.3604. View

Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A . The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A. 2005; 102(3):731-6. PMC: 545522. DOI: 10.1073/pnas.0405495102. View

Pegg A . Regulation of ornithine decarboxylase. J Biol Chem. 2006; 281(21):14529-32. DOI: 10.1074/jbc.R500031200. View

Rounbehler R, Li W, Hall M, Yang C, Fallahi M, Cleveland J . Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res. 2009; 69(2):547-53. PMC: 2749594. DOI: 10.1158/0008-5472.CAN-08-2968. View

Jung M, Kim S, Jeon G, Kim S, Kim Y, Choi K . Identification of differentially expressed genes in normal and tumor human gastric tissue. Genomics. 2000; 69(3):281-6. DOI: 10.1006/geno.2000.6338. View

Lazcoz P, Munoz J, Nistal M, Pestana A, Encio I, Castresana J . Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma. Cancer Genet Cytogenet. 2007; 174(1):1-8. DOI: 10.1016/j.cancergencyto.2006.08.014. View

10.

Maris J, Hogarty M, Bagatell R, Cohn S . Neuroblastoma. Lancet. 2007; 369(9579):2106-20. DOI: 10.1016/S0140-6736(07)60983-0. View

11.

Hogarty M, Norris M, Davis K, Liu X, Evageliou N, Hayes C . ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res. 2008; 68(23):9735-45. PMC: 2596661. DOI: 10.1158/0008-5472.CAN-07-6866. View

12.

Kanerva K, Makitie L, Pelander A, Heiskala M, Andersson L . Human ornithine decarboxylase paralogue (ODCp) is an antizyme inhibitor but not an arginine decarboxylase. Biochem J. 2007; 409(1):187-92. DOI: 10.1042/BJ20071004. View

13.

Wu S, Pena A, Korcz A, Soprano D, Soprano K . Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex. Oncogene. 1996; 12(3):621-9. View

14.

Koike C, Chao D, Zetter B . Sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cells. Cancer Res. 2000; 59(24):6109-12. View

15.

Tsuji T, Todd R, Meyer C, McBride J, Liao P, Huang M . Reduction of ornithine decarboxylase antizyme (ODC-Az) level in the 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model. Oncogene. 1998; 16(26):3379-85. DOI: 10.1038/sj.onc.1201887. View

16.

Gerner E, Meyskens Jr F . Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004; 4(10):781-92. DOI: 10.1038/nrc1454. View

17.

George R, Kenyon R, McGuckin A, Kohl N, Kogner P, Christiansen H . Analysis of candidate gene co-amplification with MYCN in neuroblastoma. Eur J Cancer. 1998; 33(12):2037-42. DOI: 10.1016/s0959-8049(97)00206-2. View

18.

Keren-Paz A, Bercovich Z, Porat Z, Erez O, Brener O, Kahana C . Overexpression of antizyme-inhibitor in NIH3T3 fibroblasts provides growth advantage through neutralization of antizyme functions. Oncogene. 2006; 25(37):5163-72. DOI: 10.1038/sj.onc.1209521. View

19.

Simoneau A, Gerner E, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H . The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2008; 17(2):292-9. PMC: 2515594. DOI: 10.1158/1055-9965.EPI-07-0658. View

20.

Ravanko K, Jarvinen K, Holtta E . Loss of p27Kip1 from cyclin E/cyclin-dependent kinase (CDK) 2 but not from cyclin D1/CDK4 complexes in cells transformed by polyamine biosynthetic enzymes. Cancer Res. 2000; 60(18):5244-53. View